Physicians' Academy for Cardiovascular Education

Kidney disease & CVD

Recently added learning

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia

3' education - Nov. 17, 2019 - Sripal Bangalore, MD, New york - AHA 2019, Philadelphia

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The role of ALP as predictor of CV events and vascular calcification in CKD

10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?

10' education - Aug. 7, 2019 - Marta Ruiz-Ortega, PhD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition

10' education - July 3, 2019 - ERA-EDTA 2019 - Vincent Brandenburg, MD

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Kamyar Kalantar-Zadeh, MD - Irvine, CA, USA

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom - Online CME

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME

Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Louise Nordfors - Stockholm, Sweden

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

10' education - Nov. 15, 2017

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

Blood pressure control in CKD in older people

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Prof. George L Bakris, MD (Chicago, IL, USA)

Understanding Diabetic Kidney Disease: What are the best options for clinical management?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##FULL_TITLE##

Renal denervation: New frontier in treating resistant hypertension

3' education - Dec. 11, 2012 - LA AHA 2012 - Dr Horst Sievert
##FULL_TITLE##

Protecting the heart and the kidney

3' education - Nov. 29, 2012
##FULL_TITLE##

CKD & MBD: what are the drivers of disease?

3' education - Apr. 10, 2012
##FULL_TITLE##

CKD & Nutrition: Role of protein intake & phosphate levels

3' education - Apr. 5, 2012
##FULL_TITLE##

HbA1c: targets & recommendations

3' education - July 25, 2011
##FULL_TITLE##

Implications from SHARP

3' education - July 21, 2011

On demand 10" video

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The role of ALP as predictor of CV events and vascular calcification in CKD

10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?

10' education - Aug. 7, 2019 - Marta Ruiz-Ortega, PhD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition

10' education - July 3, 2019 - ERA-EDTA 2019 - Vincent Brandenburg, MD

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Kamyar Kalantar-Zadeh, MD - Irvine, CA, USA

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom - Online CME

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME

Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Louise Nordfors - Stockholm, Sweden

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

10' education - Nov. 15, 2017

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

Where do GLP-1RA fit in in current and future management of CKD?

Subtitling in English, German, Italian, Spanish and French

10' education - July 26, 2021 - Frederik Persson, MD - Online CME
Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities, Frederik Persson discusses future possibilities for use of GLP-1RA in other target populations.

Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities to reduce CV events, Frederik Persson discusses future possibilities for use of GLP-1RA. With question to test your knowledge.

Treatment goals for patients with T2DM and CKD

Subtitling in English, German, Italian, Spanish and French

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.

Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.

How can GLP-1RA benefit a patient with diabetes and CKD?

Subtitling in English, German, Italian, Spanish and French

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME
There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD.

There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD. With question to test your knowledge.

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME
What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video.

What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video. With question to test your knowledge.

Prevention strategies in patients with CKD and T2DM

Subtitling in English, German, Italian, Spanish and French

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME
Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options.

Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options. With question to test your knowledge.

Clinical inertia in CKD - What is the rationale for SGLT2i?

Subtitling in English, German, Italian, Spanish and French

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME
Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.

Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD
A post hoc analysis of EMPA-REG OUTCOME explored potential mediators of the treatment effect of empagliflozin on kidney outcomes.

ERA-EDTA 2021 Prof. Wanner presents the results of a post hoc analysis of EMPA-REG OUTCOME, in which potential mediators of the treatment effect of empagliflozin on kidney outcomes were explored.

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD
The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.

The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD
Prof. Januzzi talks about the biology of natriuretic peptides and discusses their performance in patients with kidney disfunction for diagnosis and prognosis of HF.

Prof. Januzzi talks about the biology of natriuretic peptides and discusses their performance in patients with kidney disfunction for diagnosis and prognosis of HF.

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD
Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.

Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD
A post hoc analysis of patients in the CREDENCE trial with baseline eGFR <30 m:/min/1.73 m2 was performed. Prof. Bakris shares the results of this analysis,

A post hoc analysis of patients in the CREDENCE trial with baseline eGFR <30 mL/min/1.73 m² was performed. Prof. Bakris shares the results of this analysis.

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD
The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD
Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD
After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD
Recent CVOTs with GLP-1RAs included kidney outcomes as secondary endpoint. Johannes Mann presents kidney results of these trials and raises questions from a nephrologist's perspective.

Recent CVOTs with GLP-1RAs included kidney outcomes as a secondary endpoint. Johannes Mann presents kidney results of these trials and raises questions from a nephrologist's perspective.

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD
Prof. Wanner presents a case of a patient with CKD who develops diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.

Prof. Wanner presents a case of a CKD patient who has developed diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD
The mechanisms and beneficial cardiorenal effects of SGLT2 inhibitors in diabetic patients are dicussed in this video by Maria Rosa Costanzo, MD

Maria Rosa Constanzo explains the function of SGLT2 in the early proximal tubule of the kidney in detail and discusses how blockade of SGLT2 may result in beneficial effects.

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD
The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.

ERA-EDTA 2020 The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD
In this presention by prof. Mark Cooper, an overview is given of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2i, and their effect on kidney outcomes in CKD and DKD patients.

Prof. Mark Cooper gives an overview of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2 inhibitors, and their effect on kidney outcomes in CKD and DKD patients. With question

Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia

3' education - Nov. 17, 2019 - Sripal Bangalore, MD, New york - AHA 2019, Philadelphia
The ISCHEMIA-CKD trial evaluated whether there is a benefit of adding coronary angiogrpahy and revascularization to OMT in patients with advanced CKD and at least moderate ischemia.

AHA 2019 The ISCHEMIA-CKD trial evaluated whether there is a benefit of adding coronary angiogrpahy and revascularization to OMT in patients with advanced CKD and at least moderate ischemia.

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner
Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.

Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.

The role of ALP as predictor of CV events and vascular calcification in CKD

10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD
Alkaline phosphatase (ALP) is a potential novel treatment target for CVD in CKD. Dr. Haarhaus discusses ALP-related mechanisms of increased CV risk and beneficial effects of the BET inhibitor apabetalone.

Alkaline phosphatase (ALP) is a potential novel treatment target for CVD in CKD. Dr. Haarhaus discusses ALP-related mechanisms of increased CV risk and beneficial effects of the BET inhibitor apabetalone.

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME
Paola Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.

Paola Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME
Dr. Herrington summarizes key randomized data from completed large placebo-controlled SGLT2-inhibitor trials and describes ongoing SGLT2i trials in diabetes, renal and HF populations.

Dr. Herrington summarizes key randomized data from completed large placebo-controlled SGLT2-inhibitor trials and describes ongoing SGLT2i trials in diabetes, renal and HF populations.

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME
Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.

Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.

Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?

10' education - Aug. 7, 2019 - Marta Ruiz-Ortega, PhD
Epigenetic processes are involved in renal damage. Marta Ruiz-Ortega describes the role of vascular calcification and alkaline phosphatase (ALP) in CKD and effects of BET inhibition on vascular calcification.

Epigenetic processes are involved in renal damage. Marta Ruiz-Ortega describes the role of vascular calcification and alkaline phosphatase (ALP) in CKD and effects of BET inhibition on vascular calcification.

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the mangement of CKD with resistant hypertension.

Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the management of CKD with resistant hypertension.

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME
Prof. Agarwal discusses the current standard of care  in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.

Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.

Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition

10' education - July 3, 2019 - ERA-EDTA 2019 - Vincent Brandenburg, MD
Epigenetics contribute to vascular calcification, which is a hallmark of CVD in CKD. Prof. Brandenburg explains how BET inhibition can interfere with factors and pathways associated with vascular calcification.

ERA-EDTA 2019 Epigenetics contribute to vascular calcification, which is a hallmark of CVD in CKD. Prof. Brandenburg explains how BET inhibition can interfere with factors and pathways associated with vascular calcification.

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD
Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019
Prof. Rossignol talks about the AMBER trial and a prespecified analysis of HF patients. Patiromer use resulted in higher spironolactone maintenance in patients with resistant hypertension and CKD.

ESC HF 2019 Prof. Rossignol talks about the AMBER trial and a prespecified analysis of HF patients. Patiromer use resulted in higher spironolactone maintenance in patients with resistant hypertension and CKD.

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada
Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019
Use of canagliflozin in T2DM patients with kidney disease resulted in reduction of renal and CV outcomes, irrespective of baseline kidney dysfunction. Prof Carol Pollock discusses the results of the CREDENCE trial.

ISN-WCN 2019 Use of canagliflozin in T2DM patients with kidney disease resulted in reduction of renal and CV outcomes, irrespective of baseline kidney dysfunction. Prof Carol Pollock discusses the results of the CREDENCE trial.

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia
Prof. Hiddo Lambers Heerspink dissusses the unique design of the SONAR trial and the findings with atrasentan therapy in patients with diabetic kidney disease.

ISN-WCN 2019 Prof. Hiddo Lambers Heerspink dissusses the unique design of the SONAR trial and the findings with atrasentan therapy in patients with diabetic kidney disease.

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia
The SONAR trial was designed to safely test the effect of atrasentan in a selected group of high-risk T2DM patients with kidney disease. This proved to be a good approach, as results were very positive.

ISN-WCN 2019 The SONAR trial was designed to safely test the effect of atrasentan in a selected group of high-risk T2DM patients with kidney disease. This proved to be a good approach, as results were very positive.

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia
Prof. Perkovic summarizes the results of the CREDENCE trial that tested the SGLT2 inhibitor canagliflozin. It is a safe drug that prevents kidney failure and CV complications in people with diabetes and kidney disease.

ICN-WCN 2019 Prof. Perkovic summarizes the results of the CREDENCE trial that tested the SGLT2 inhibitor canagliflozin. It is a safe drug that prevents kidney failure and CV complications in people with diabetes and kidney disease.

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD
Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits.

Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD
Prof. Montanya DMdiscusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trials, respectively.

Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.

A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Kamyar Kalantar-Zadeh, MD - Irvine, CA, USA
Kalantar shares data that suggest that epigenetic modification with the BET inhibitor apabetalone may improve factors involved in the pathogenesis of CKD, including alkaline phosphatase.

Kalantar shares data that suggest that epigenetic modification with the BET inhibitor apabetalone may improve factors involved in the pathogenesis of CKD, including alkaline phosphatase.

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CKD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.

Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CKD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME
Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.

Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME
Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom - Online CME
Prof Baigent discusses the key areas of uncertainty of treatment with SGLT2 inhibitors in patients with CKD and what ongoing trials will likely contribute to our understanding of this drug class.

Prof Baigent discusses the key areas of uncertainty of treatment with SGLT2 inhibitors in patients with CKD and what ongoing trials will likely contribute to our understanding of this drug class.

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME
Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Louise Nordfors - Stockholm, Sweden
Louise Nordfors describes several epigenetic mechanisms that have been described to be dysregulated in human disease and the rationale for BET protein inhibition to treat CV and renal disease.

Louise Nordfors describes several epigenetic mechanisms that have been described to be dysregulated in human disease and the rationale for BET protein inhibition to treat CV and renal disease.

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA
A new analysis of the CANTOS trial showed that IL-1β inhibition with canakinumab in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.

ACC 2018 A new analysis of the CANTOS trial showed that IL-1β inhibition in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

10' education - Nov. 15, 2017
Prof. Neil Poulter gives an overview of a subgroup analysis of the LEADER trial in which patients with CKD treated with liraglutide showed a reduction of CV events as compared with those on placebo treatment.

Prof. Neil Poulter gives an overview of a subgroup analysis of the LEADER trial in which patients with CKD treated with liraglutide showed a reduction of CV events as compared with those on placebo treatment.

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA
Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.

Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain
Luis M Ruilope, MD looks at the evidence showing that currently available therapies leave room for improvement in the reduction of CV events in patients with diabetes and chronic kidney disease.

Luis M Ruilope, MD looks at the evidence showing that currently available therapies leave room for improvement in the reduction of CV events in patients with diabetes and chronic kidney disease.

Blood pressure control in CKD in older people

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Prof. George L Bakris, MD (Chicago, IL, USA)
Prof. George Bakris, MD, recommends to balance the benefit of BP-lowering on the heart and the kidney in older people. BP control is vital to slow progression of CKD, but a too low BP can be harmful.

Prof. George Bakris, MD, recommends to balance the benefit of BP-lowering on the heart and the kidney in older people. BP control is vital to slow progression of CKD, but a too low BP can be harmful.

Understanding Diabetic Kidney Disease: What are the best options for clinical management?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland

Dr. Per-Henrik Groop outlines that diabetic kidney disease is common and associated with a grim prognosis. Optimal glucose control is central to limiting the risk of renal complications. Newer antidiabetic drugs can play a welcome role to optimally treat these patients.

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

Very recently, data became available of use of the SGLT2-inhibitor empagliflozin in patients with diabetic kidney disease, a condition associated with increased risk of CV complications. Prof. Groop shares the data that suggest that empagliflozin can reduce or prevent the onset of this condition.

Renal denervation: New frontier in treating resistant hypertension

3' education - Dec. 11, 2012 - LA AHA 2012 - Dr Horst Sievert
##KEY_PHRASE##

Dr Horst Sievert, Germany, highlights current status of catheter based techniques to treat resistant hypertension.

Protecting the heart and the kidney

3' education - Nov. 29, 2012
##KEY_PHRASE##

Dr Christina Reith, Oxford about new insights from the SHARP and its implications for clinical practice

CKD & MBD: what are the drivers of disease?

3' education - Apr. 10, 2012
##KEY_PHRASE##

Prof. John Cunningham (London, United Kingdom) discusses what are the responses to a decrease of GFR on kidney disease and how these can be triggered.

CKD & Nutrition: Role of protein intake & phosphate levels

3' education - Apr. 5, 2012
##KEY_PHRASE##

Prof. Denis Fouque (Lyon, France) discusses the role of protein intake on renal function and on phosphate levels.

HbA1c: targets & recommendations

3' education - July 25, 2011
##KEY_PHRASE##

In this expert opinion prof. Guntram Schernthaner discusses the optimal target value of HbA1c, in diabetes or if combined with cardiovascular disease or renal impairment.

Implications from SHARP

3' education - July 21, 2011
##KEY_PHRASE##

Prof Jane Armitage, Oxford discusses the results and the implications of the Study of Heart and Renal Protection (SHARP ) with prof John Betteridge  London, UK.